• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.

作者信息

Sood Siddhartha, Rimke Alexander, Rankin Brian D, Abduelmula Abrahim, Georgakopoulos Jorge R, Maliyar Khalad, Bagit Ahmed, Leung Fernejoy, Devani Alim R, Vender Ronald, Yeung Jensen, Prajapati Vimal H

机构信息

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Calgary, AB, T2J 7E1, Canada.

出版信息

Am J Clin Dermatol. 2025 Mar;26(2):301-304. doi: 10.1007/s40257-025-00922-2. Epub 2025 Feb 3.

DOI:10.1007/s40257-025-00922-2
PMID:39900871
Abstract
摘要

相似文献

1
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.成人患者中先前使用过白细胞介素-23抑制剂的斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项多中心回顾性研究
Am J Clin Dermatol. 2025 Mar;26(2):301-304. doi: 10.1007/s40257-025-00922-2. Epub 2025 Feb 3.
2
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.在既往使用过白细胞介素-17抑制剂的成年斑块状银屑病患者中使用比美吉珠单抗的真实世界经验：一项为期16周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Dec;91(6):1265-1267. doi: 10.1016/j.jaad.2024.07.1515. Epub 2024 Aug 23.
3
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review.
J Am Acad Dermatol. 2025 May;92(5):1093-1095. doi: 10.1016/j.jaad.2024.12.034. Epub 2025 Jan 20.
4
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review".
J Am Acad Dermatol. 2025 Jun;92(6):e191-e193. doi: 10.1016/j.jaad.2024.11.083. Epub 2025 Feb 14.
5
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).比美吉珠单抗治疗斑块状银屑病的有效性和安全性：一项真实世界多中心研究-IL PSO（意大利银屑病情况）
Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.
6
Response to Sood et al's "Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review".
J Am Acad Dermatol. 2025 Jun;92(6):e189-e190. doi: 10.1016/j.jaad.2024.10.129. Epub 2025 Feb 15.
7
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗老年患者的疗效和安全性：真实世界多中心回顾性研究-IL PSO（意大利银屑病景观）。
J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.
8
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗累及生殖器的斑块状银屑病：一项为期16周的多中心真实世界研究——IL PSO（意大利银屑病概况）
Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.
9
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.用于治疗斑块状银屑病的比美吉珠单抗-bkzx：药物综述
Ann Pharmacother. 2025 Jun;59(6):577-584. doi: 10.1177/10600280241288553. Epub 2024 Oct 19.
10
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.成人斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项为期52周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15.

本文引用的文献

1
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.成人斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项为期52周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15.
2
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.成人斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项为期16周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.
3
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study.
布罗达单抗在既往生物治疗失败后的中重度斑块状银屑病中的疗效：一项4期、多中心、开放标签研究。
J Am Acad Dermatol. 2024 Jun;90(6):1254-1256. doi: 10.1016/j.jaad.2024.01.025. Epub 2024 Jan 28.
4
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).比美吉珠单抗治疗斑块状银屑病的有效性和安全性：一项真实世界多中心研究-IL PSO（意大利银屑病情况）
Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.
5
Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.在中度至重度银屑病患者中切换生物制剂：来自法国队列 PSOBIOTEQ 的结果。
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2101-2112. doi: 10.1111/jdv.18409. Epub 2022 Jul 22.
6
Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.全国性研究：生物治疗难治性银屑病和超应答者的流行情况及特征。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1284-1291. doi: 10.1111/jdv.18126. Epub 2022 Apr 12.
7
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.